Dual Specificity Protein Kinase TTK Inhibitor Market, By Product Type (S 81694, BAY 1217389, BOS-172722, CFI-402257, Others), By Application (Non-haematologic Malignancies, Breast Cancer, Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Others), By End User (Hospitals, Specialty Clinics, Others (Cancer Research Institutes, etc.)), By geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023

Code : CMI2373

Pages :180

Formats :

Excel and PDF

Industry : Biotechnology

Dual Specificity Protein Kinase TTK Inhibitor MarketSize and Trends

The global dual specificity protein kinase Ttk inhibitor market is estimated to be valued at US$ 76.6 million in 2023 and is expected to exhibit a CAGR of 22.3% during the forecast period (2023-2030).

Figure 1. Global Dual Specificity Protein Kinase Ttk Inhibitor Market Share (%), By Product Type, 2023

Global Dual Specificity Protein Kinase Ttk Inhibitor Market– Drivers

Increasing prevalence of cancer is expected to drive the market growth during the forecast period: The increasing prevalence of different types of cancers, such as solid tumor, breast cancer, metastatic breast cancer, colorectal cancer, solid tumor, prostate cancer, pancreatic ductal adenocarcinoma, and others, is expected to drive the global dual specificity protein kinase Ttk inhibitor market growth over the forecast period. For instance, in 2020, according to the America Association of Cancer, approximately 1,414,259 people were diagnosed with prostate cancer.

Increasing number of pipeline molecules of dual specificity protein kinase Ttk inhibitor: The increasing number of pipeline molecules of dual specificity protein kinase Ttk inhibitor as targeted therapies for various types of cancer such as breast cancer, and others, which is expected to propel the global dual specificity protein kinase Ttk inhibitor market growth over the forecast period. For instance, on January 11, 2023, the U.S. Food and Drug Administration (U.S. FDA) granted a fast-track designation to threonine tyrosine kinase (Ttk) inhibitor CFI-402257 for monotherapy, which is used in combination with fulvestrant (Faslodex), for the treatment of adult patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.

Figure 2. Global Dual Specificity Protein Kinase Ttk Inhibitor Market Share (%), By Region, 2023